On December 4, 2020, Regulus Therapeutics Inc. closed the transaction. The company issued 24,341,607 shares at $0.622 per common share, 272,970 non-voting Class A-3 convertible preferred stock at $6.22 per convertible preferred stock, and 20,303,480 warrants at $0.125 per warrant for aggregate gross proceeds of $19,383,036.94. The transaction included participation from 18 investors pursuant to regulation D. The transaction included participation from Growth Equity Opportunities V, LLC for 4,999,994.73, USAA Mutual Funds Trust - USAA Science & Technology Fund (MutualFund:USSC.X) and Victory Portfolios - Victory RS Science and Technology Fund (MutualFund:RIFY.X), funds managed by Victory Capital Management Inc. for $5,753,619.36, Point72 Associates, LLC, a fund managed by S.A.C. Capital Management, LLC for $2,301,448.32, Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP, MSI BVF SPV, LLC, funds managed by BVF Partners LP for $2,416,520.13, and Stelios Papadopoulos, Chairman of the Board of the company for $ 574,395.24, Joseph Hagan, Chief Executive Officer and Director of the company for $28,722.37, Richard E. Gormley for $28,770.29, and Noam Rubinstein for $402,755.39.